Kestra Medical Technologies, Ltd.
KMTS Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 26, 2026
$29.42
KIRA · Stoqly’s AI analyst, in plain words
- Kestra Medical Technologies, Ltd. had $95.1M of revenue in fiscal 2026, up 59.0% on the year before.
- Its operating margin was −141.6%, up 36.2 pts: of every 100 in sales, about −142 is left after running the business.
- Kestra Medical Technologies, Ltd. lost $132M in fiscal 2026.
- Free cash flow was −$117M in fiscal 2026, −122.6% of revenue.
- Kestra Medical Technologies, Ltd. has $154M more cash than debt.
Market cap
$1.7B
P/E
—
Revenue
$95.1M
Net income
−$132M
Free cash flow
−$117M
Operating margin
−141.6%
Kestra Medical Technologies, Ltd. in 30 seconds · fiscal 2026
Are sales growing?
+59.0%
Yes. Sales grew 59.0% last year.
Does it make a profit?
−138.4%
No. It lost money last year.
Does profit turn into cash?
−122.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
5 / 9
Mixed. It passes 5 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Kestra Medical Technologies, Ltd. does
No business description yet.
- Fiscal year ends
- April 30, 2026
- Latest annual report
- 10-K · Jul 14, 2026
- Legal name
- KESTRA MEDICAL TECHNOLOGIES, LTD.
- CIK
- 0001877184
Kestra Medical Technologies, Ltd. · KMTS
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 | FY26 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $27.8M | $59.8M | $95.1M |
| Revenue growth | — | 115.1% | 59.0% |
| Gross margin | 1.3% | 40.5% | 51.4% |
| Operating margin | −305.8% | −177.8% | −141.6% |
| Net income | −$94.1M | −$114M | −$132M |
| Net margin | −338.4% | −190.3% | −138.4% |
| Diluted EPS | −$5.07 | −$5.13 | −$2.43 |
| Cash | |||
| Cash from operations | −$72.2M | −$77.6M | −$81.7M |
| Capital expenditure | $12.2M | $22.9M | $34.9M |
| Free cash flow | −$84.5M | −$101M | −$117M |
| FCF margin | −303.7% | −168.1% | −122.6% |
| Share count change | — | 23.6% | 120.4% |
| Debt and strength | |||
| Cash and short-term investments | $8.2M | $238M | $196M |
| Debt incl. finance leases | $42.5M | $41.1M | $42.6M |
| Shareholders' equity | −$209M | $205M | $260M |
| Current ratio | 0.5x | 6.7x | 4.4x |
| Interest coverage | −13.7x | −13.8x | −17.9x |
| Returns and quality | |||
| Return on capital | — | −943.3% | −100.5% |
| Return on equity | — | — | −56.6% |
| Return on tangible equity | — | −61.4% | −50.7% |
| Piotroski F-score | — | 5 | 5 |
| Altman Z'' | −46.7 | −0.9 | −2.5 |
Insiders bought, 12 months
$0.2M
1 insider
Insiders sold, 12 months
$12.1M
11 insiders
Of sales under plans
61%
$7.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Kestra Medical Technologies, Ltd. · KMTS
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $29.42 a share, the company is worth $1.7B.
Source: SEC EDGAR XBRL filings (CIK 0001877184). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.